Presentations Media coverage

Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.

Half of all cancer patients fail chemotherapy. This resistance increases mortality and represents a major burden for the health care system.



CEO, Nils Brünner says “Scandion Oncology is extremely proud to be listed on Spotlight Stock Market and had it first day of trading shares on Nov. ...

Scandion Oncology – Sedermeradagen Göteborg 2018

Bolaget Scandion Oncology presenterar på Sedermeradagen i Göteborg den 11 oktober 2018.

Presentation – Investerarträff Copenhagen, October 4, 2018

Scandion Oncology med vd Nils Brünner presenterar live i Köpenhamn torsdagen den 4. oktober 2018.

Scandion Oncology presents at Sedermeradagen Malmö 2018

Scandion Oncology på Sedermeradagen i Malmö 2018

Presentation – Scandion Oncology

Scandion Oncology was formed as a spin-out company from the University of Copenhagen and the research and development company Saniona AB in 2017 for t...

Market analysis

Long range strategic patient and commercial forecast. The value SCO-101 offer to patients and healthcare providers targeting breat- and colorectal can...

Fact sheet

Factsheet about Scandion Oncology

Media coverage

Scandion Oncology – going on the stock exchange


Interview – Investerarträff Copenhagen, October 4, 2018

I en intervju med berättar CEO Nils Brünner om bolaget, marknaden och planerna framåt.